Skip to main content
. 2022 Jul 7;12(8):1777–1792. doi: 10.1007/s13555-022-00760-8

Fig. 4.

Fig. 4

Risk ratios (95% CrI) of achieving PASI 75, PASI 90 and PASI 100 for bimekizumab 320 mg versus other treatments (REZ, adjusted, random-effects multinomial model). Treatments are sorted by the highest to lowest probabilities of reaching PASI 75. CrI credible interval, IL interleukin, PASI Psoriasis Area and Severity Index, TNF tumour necrosis factor